Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review

Neuroscience and Biobehavioral Reviews

Volumn 34, Issue 3, 2010, Pages 408-437

  Low, Lee Fay ^a   Yap, Melvyn H W ^a   Brodaty, Henry ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; Apolipoprotein E; Dementia; Gene environment interactions; Risk factors; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIPERSPIRANT AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; C REACTIVE PROTEIN; CORTICOSTEROID; ESTRADIOL; HOMOCYSTEINE; NONSTEROID ANTIINFLAMMATORY AGENT; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; BLOOD PRESSURE; BLOOD TRANSFUSION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIET; ENVIRONMENTAL FACTOR; FAT INTAKE; HEAD INJURY; HERPES SIMPLEX VIRUS; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; INSULIN RESPONSE; LIFESTYLE; LIPID ANALYSIS; MENTAL PERFORMANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; STOMACH ULCER; STROKE; SYSTEMATIC REVIEW; THYROID DISEASE; WAIST CIRCUMFERENCE; WEIGHT CHANGE;

APOLIPOPROTEINS E; DEMENTIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 72449200083     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2009.08.007     Document Type: Review

References (135)

1. Abbott R.D., White L.R., Ross G.W., Masaki K.H., Curb J.D., and Petrovitch H. Walking and dementia in physically capable elderly men. JAMA 22 (2004) 1447-1453
2. Aggarwal N.T., Bienias J.L., Bennett D.A., Wilson R.S., Morris M.C., Schneider J.A., et al. The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology 26 (2006) 140-146
3. Anstey K.J., Lipnicki D.M., and Low L.F. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am. J. Geriatr. Psychiatry 16 (2008) 343-354
4. Anstey K.J., von Sanden C., Salim A., and O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am. J. Epidemiol. (2007) 116
5. Anttila T., Helkala E.-L., Viitanen M., Kareholt I., Fratiglioni L., Winblad B., et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. Br. Med. J. 329 (2004) 530-539
6. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70 (2008) 1795-1802
7. Asada T., Yamagata Z., Motonaga T., Kimura M., and Uno M. Smoking and risk of Alzheimer's disease. Lancet 352 (1998) 818-819
8. Bachman D.L., Green R.C., Benke K.S., Cupples L.A., and Farrer L.A. Comparison of Alzheimer's disease risk factors in white and African American families. Neurology 60 (2003) 1372-1374
9. Barberger-Gateau P., Raffaitin C., Letenneur L., Berr C., Tzourio C., Dartigues J.F., et al. Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 69 (2007) 1921-1930
10. Baum L., Lam L.C., Kwok T., Lee J., Chiu H.F., Mok V.C., et al. Apolipoprotein E epsilon4 allele is associated with vascular dementia. Dement. Geriatr. Cogn. Disord. 22 (2006) 301-305
11. Beffert U. Herpes simplex virus type 1 in the brain, apolipoprotein E genotype and Alzheimer's disease. McGill J. Med. 4 (1998) 4-8
12. Beydoun M.A., Beydoun H.A., and Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev. 9 (2008) 204-218
13. Biessels G.J., Staekenborg S., Brunner E., Brayne C., and Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5 (2006) 64-74
14. Blacker D., Haines J.L., Rodes L., Terwedow H., Go R.C.P., Harrell L.E., et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 48 (1997) 139-147
15. Borenstein A.R., Wu Y., Mortimer J.A., Schellenberg G.D., McCormick W.C., Bowen J.D., et al. Developmental and vascular risk factors for Alzheimer's disease. Neurobiol. Aging 26 (2005) 325-334
16. Borroni B., Grassi M., Costanzi C., Archetti S., Caimi L., and Padovani A. APOE genotype and cholesterol levels in Lewy body dementia and Alzheimer disease: Investigating genotype-phenotype effect on disease risk. Am. J. Geriatr. Psychiatry 14 (2006) 1022-1031
17. Botto L.D., and Khoury M.J. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am. J. Epidemiol. 153 (2001) 1016-1020
18. Carlson M.C., Helms M.J., Steffens D.C., Burke J.R., Potter G.G., and Plassman B.L. Midlife activity predicts risk of dementia in older male twin pairs. Alzheimer's Dement. 4 (2008) 324-331
19. Cedazo-Mínguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 11 (2007) 1227-1238
20. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7 (1994) 180-184
21. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
22. Cornelius C., Fastbom J., Winblad B., and Viitanen M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 23 (2004) 135-143
23. Craig M.C., Maki P.M., and Murphy D.G. The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol. 4 (2005) 190-194
24. Cramer C., Haan M.N., Galea S., Langa K.M., and Kalbfleisch J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71 (2008) 344-350
25. Cupples A.L., Weinberg J., Beiser A., Auerbach S.H., Volicer L., Cipolloni B.P., et al. Effects of smoking, alcohol and APOE genotype on Alzheimer disease: the MIRAGE study. Alzheimer's Rep. 3 (2000) 105-114
26. Dai Q., Borenstein A.R., Wu Y., Jackson J.C., and Larson E.B. Fruit and vegetable juices and Alzheimer's disease: The Kame Project. Am. J. Med. 119 (2006) 751-759
27. de Craen A.J.M., Gussekloo J., Vrijsen B., and Westendorp R.G.J. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am. J. Epidemiol. 161 (2005) 114-120
28. De Leeuw F.E., Richard F., De Groot J.C., Van Duijn C.M., Hofman A., Van Gijn J., et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 35 (2004) 1057-1060
29. DeKosky S.T., Williamson J.D., Fitzpatrick A.L., Kronmal R.A., Ives D.G., Saxton J.A., et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300 (2008) 2253-2262
30. Duara R., Barker W.W., Lopez-Alberola R., Loewenstein D.A., Grau L.B., Gilchrist D., et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 46 (1996) 1575-1579
31. Dufouil C., Richard F., Fiavet N., Dartigues J.F., Ritchie K., Tzourio C., et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. Neurology 64 (2005) 1531-1538
32. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287 (2002) 3223-3229
33. Ernst E. Diet and dementia, is there a link? A systematic review. Nutr. Neurosci. 2 (1999) 1-6
34. Evans R.M., Emsley C.L., Gao S., Sahota A., Hall K.S., Farlow M.R., et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54 (2000) 240-242
35. Farrer L.A., Brin M.F., Elsas L., Goate A., Kennedy J., Mayeux R., et al. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 274 (1995) 1627-1629
36. Farrer L.A.P., Cupples L.A.P., Haines J.L.P., Hyman B.M.D.P., Kukull W.A.P., Mayeux R.M.D., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278 (1997) 1349-1356
37. Fleminger S., Oliver D.L., Lovestone S., Rabe-Hesketh S., and Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J. Neurol. Neurosurg. Psychiatry 74 (2003) 857-862
38. Geerlings M.I., Strozyk D., Masaki K., Remaley A.T., Petrovitch H., Ross G.W., et al. Endogenous sex hormones, cognitive decline, and future dementia in old men. Ann. Neurol. 60 (2006) 346-355
39. Gillette-Guyonnet S., Abellan Van Kan G., Andrieu S., Barberger-Gateau P., Berr C., Bonnefoy M., et al. Iana task force on nutrition and cognitive decline with aging. J. Nutr. Health Aging 11 (2007) 132-152
40. Gorospe E.C., and Dave J.K. The risk of dementia with increased body mass index. Age Ageing 36 (2007) 23-29
41. Green R.C., McNagny S.E., Jayakumar P., Cupples L.A., Benke K., and Farrer L.A. Statin use and the risk of Alzheimer's disease: The MIRAGE Study. Alzheimer's Dement. 2 (2006) 96-103
42. Gustafson D., Rothenberg E., Blennow K., Steen B., and Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 163 (2003) 1524-1528
43. Haan M.N., Aiello A.E., West N.A., and Jagust W.J. C-reactive protein and rate of dementia in carriers and non carriers of apolipoprotein APOE4 genotype. Neurobiol. Aging 29 (2008) 1774-1782
44. Haan M.N., Shemanski L., Jagust W.J., Manolio T.A., and Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282 (1999) 40-46
45. Hall K., Murrell J., Ogunniyi A., Deeg M., Baiyewu O., Gao S., et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66 (2006) 223-227
46. Henderson A.S., Jorm A.F., Christensen H., Jacomb P.A., and Korten A.E. Aspirin, anti-inflammatory drugs and risk of dementia. Int. J. Geriatr. Psychiatry 12 (1997) 926-930
47. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 (1997) 151-154
48. Hogervorst E., Lehmann D.J., Warden D.R., McBroom J., and Smith A.D. Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer's disease in men. Int. J. Geriatr. Psychiatry 17 (2002) 938-940
49. Huang T.L., Zandi P.P., Tucker K.L., Fitzpatrick A.L., Kuller L.H., Fried L.P., et al. Benefits of fatty fish on dementia risk are stronger for those without APOE e4. Neurology 65 (2005) 1409-1414
50. in't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515-1521
51. Irie F., Fitzpatrick A.L., Lopez O.L., Kuller L.H., Peila R., Newman A.B., et al. Enhanced risk for Alzheimer disease in persons with Type 2 diabetes and APOE epsilon 4: The Cardiovascular Health Study Cognition Study. Arch. Neurol. 65 (2008) 89-93
52. Irie F., Masaki K.H., Petrovitch H., Abbott R.D., Ross G.W., Taaffe D.R., et al. Apolipoprotein E 4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: The Honolulu-Asia aging study. Arch. Gen. Psychiatry 65 (2008) 906-912
53. Itabashi S., Arai H., Matsui T., Higuchi S., and Sasaki H. Herpes simplex virus and risk of Alzheimer's disease. Lancet 349 (1997) 1102
54. Itzhaki R.F., Lin W.R., Shang D., Wilcock G.K., Faragher B., and Jamieson G.A. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 349 (1997) 241-244
55. Ivan C.S., Seshadri S., Beiser A., Au R., Kase C.S., Kelly-Hayes M., et al. Dementia after stroke: The Framingham study. Stroke 35 (2004) 1264-1268
56. Jacomb P.A., Jorm A.F., Korten A.E., Christensen H., and Henderson A.S. Predictors of refusal to participate: a longitudinal health survey of the elderly in Australia. BMC Public Health (2002) 2
57. Jarvik G.P., Wijsman E.M., Kukull W.A., Schellenberg G.D., Yu C., and Larson E.B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45 (1995) 1092-1096
58. Jin Y.P., Ostbye T., Feightner J.W., Di Legge S., and Hachinski V. Joint effect of stroke and APOE 4 on dementia risk: The Canadian Study of Health and Aging. Neurology 70 (2008) 9-16
59. Johnston J.M., Nazar-Stewart V., Kelsey S.F., Kamboh M.I., and Ganguli M. Relationships between cerebrovascular events, APOE polymorphism and Alzheimer's disease in a community sample. Neuroepidemiology 19 (2000) 320-326
60. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 7 (2008) 812-826
61. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., et al. Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch. Neurol. (2006) 63.65.noc60013
62. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62 (2005) 1556-1560
63. Kivipelto M., Rovio S., Ngandu T., Kåreholt I., Eskelinen M., Winblad B., et al. Apolipoprotein E e4 magnifies lifestyle risks for dementia: a population-based study. J. Cell. Mol. Med. 12 (2008) 2762-2771
64. Knol M.J., van der Tweel I., Grobbee D.E., Numans M.E., and Geerlings M.I. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int. J. Epidemiol. 36 (2007) 1111-1118
65. Kuller L.H. Green Banana*: dementia epidemiology research: it is time to modify the focus of research. J. Gerontol. A Biol. Sci. Med. Sci. 61 (2006) 1314-1318
66. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br. Med. J. 315 (1997) 1045-1049
67. Laitinen M.H., Ngandu T., Rovio S., Helkala E.L., Uusitalo U., Viitanen M., et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement. Geriatr. Cogn. Disord. 22 (2006) 99-107
68. Laurin D., Masaki K.H., Foley D.J., White L.R., and Launer L.J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia aging study. Am. J. Epidemiol. 159 (2004) 959-967
69. Laurin D., Masaki K.H., White L.R., and Launer L.J. Ankle-to-brachial index and dementia. The Honolulu-Asia Aging Study. Circulation (2007)
70. Lautenschlager N.T., and Almeida O.P. Physical activity and cognition in old age. Curr. Opin. Psychiatry 19 (2006) 190-193
71. LeBlanc E.S., Janowsky J., Chan B.K., and Nelson H.D. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285 (2001) 1489-1499
72. Li G., Shofer J.B., Kukull W.A., Peskind E.R., Tsuang D.W., Breitner J.C.S., et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65 (2005) 1045-1050
73. Lindsay J., Laurin D., Verreault R., Hebert R., Helliwell B., Hill G.B., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 156 (2002) 445-453
74. Low L.F., and Anstey K.J. Hormone replacement therapy and cognitive performance in postmenopausal women-a review by cognitive domain. Neurosci. Biobehav. Rev. 30 (2006) 66-84
75. Luchsinger J.A., Tang M.X., and Mayeux R. Glycemic load and risk of Alzheimer's disease. J. Nutr. Health Aging 11 (2007) 238-241
76. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch. Neurol. 59 (2002) 1258-1263
77. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 60 (2003) 203-208
78. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63 (2004) 1187-1192
79. Luchsinger J.A., Tang M.X., Shea S., Miller J., Green R., and Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62 (2004) 1972-1976
80. Luchsinger J.A., Tang M.X., Siddiqui M., Shea S., and Mayeux R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc. 52 (2004) 540-546
81. Luukinen H., Jokelainen J., Kervinen K., Kesäniemi Y.A., Winqvist S., and Hillbom M. Risk of dementia associated with the ApoE e4 allele and falls causing head injury without explicit traumatic brain injury. Acta Neurol. Scand. 118 (2008) 153-158
82. Luukinen H., Viramo P., Herala M., Kervinen K., Kesaniemi Y.A., Savola O., et al. Fall-related brain injuries and the risk of dementia in elderly people: a population-based study. Eur. J. Neurol. 12 (2005) 86-92
83. Martins C.A.R., Oulhaj A., De Jager C.A., and Williams J.H. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 65 (2005) 1888-1893
84. McGuinness B., Todd S., Passmore A.P., and Bullock R. Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J. Neurol. Neurosurg. Psychiatry 79 (2008) 4-5
85. Mehta K.M., Ott A., Kalmijn S., Slooter A.J.C., Van Duijn C.M., Hofman A., et al. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study. Neurology 53 (1999) 1959-1962
86. Merchant C., Tang M.X., Albert S., Manly J., Stern Y., and Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 52 (1999) 1408-1412
87. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., et al. Dietary fats and the risk of incident Alzheimer disease. Arch. Neurol. 60 (2003) 194-200
88. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287 (2002) 3230-3237
89. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 60 (2003) 940-946
90. Morris M.C., Evans D.A., Schneider J.A., Tangney C.C., Bienias J.L., and Aggarwal N.T. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J. Alzheimer's Dis. 9 (2006) 435-443
91. Mukamal K.J., Kuller L.H., Fitzpatrick A.L., Longstreth Jr. W.T., Mittleman M.A., and Siscovick D.S. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 289 (2003) 1405-1413
92. Nathan B.P., Barsukova A.G., Shen F., McAsey M., and Struble R.G. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 145 (2004) 3065-3073
93. Newman A.B., Fitzpatrick A.L., Lopez O., Jackson S., Lyketsos C., Jagust W., et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study Cohort. J. Am. Geriatr. Soc. 53 (2005) 1101-1107
94. O'Meara E.S., Kukull W.A., Schellenberg G.D., Bowen J.D., McCormick W.C., Teri L., et al. Alzheimer's disease and history of blood transfusion by apolipoprotein-E genotype. Neuroepidemiology 16 (1997) 86-93
95. O'Meara E.S., Kukull W.A., Sheppard L., Bowen J.D., McCormick W.C., Teri L., et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am. J. Epidemiol. 146 (1997) 373-384
96. Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256-1262
97. Peters R., Beckett N., Forette F., Tuomilehto J., Clarke R., Ritchie C., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7 (2008) 683-689
98. Peters R., Peters J., Warner J., Beckett N., and Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 37 (2008) 505-512
99. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 (2005) 2379-2388
100. Petot, G., Cook, T., Chen, C.H., Reidel, T., Debanne, S.M., Koss, E., et al., 2000. A high fat diet during adulthood increases risk for Alzheimer's disease for those with the Apoe-ε4 allele.
101. Plassman B.L., Havlik R.J., Steffens D.C., Helms M.J., Newman T.N., Drosdick D., et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 55 (2000) 1158-1166
102. Podewils L.J., Guallar E., Kuller L.H., Fried L.P., Lopez O.L., Carlson M., et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am. J. Epidemiol. 161 (2005) 639-651
103. Poels M.M.F., van Oijen M., Mattace-Raso F.U.S., Hofman A., Koudstaal P.J., Witteman J.C.M., et al. Arterial stiffness, cognitive decline, and risk of dementia: The Rotterdam Study. Stroke 38 (2007) 888-892
104. Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimer's Dement. 4 (2008) S91-S97
105. Potter G.G., Helms M.J., Burke J.R., Steffens D.C., and Plassman B.L. Job demands and dementia risk among male twin pairs. Alzheimer's Dement. 3 (2007) 192-199
106. Qiu C., Winblad B., Fastbom J., and Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology 61 (2003) 655-660
107. Qiu C., Winblad B., and Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4 (2005) 487-499
108. Raffaitin C., Gin H., Empana J.-P., Helmer C., Berr C., Tzourio C., et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: The Three-City Study. Diabetes Care 32 (2008) 169-174
109. Reitz C., Den Heijer T., Van Duijn C., Hofman A., and Breteler M.M.B. Relation between smoking and risk of dementia and Alzheimer disease: The Rotterdam Study. Neurology 69 (2007) 998-1005
110. Rippon G.A., Tang M.X., Lee J.H., Lantigua R., Medrano M., and Mayeux R. Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology 66 (2006) 35-40
111. Ronnemaa E., Zethelius B., Sundelof J., Sundstrom J., Degerman-Gunnarsson M., Berne C., et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71 (2008) 1065-1071
112. Rosvall L., Rizzuto D., Wang H.-X., Winblad B., Graff C., and Fratiglioni L. APOE-related mortality: Effect of dementia, cardiovascular disease and gender. Neurobiol. Aging. 30 (2009) 1545-1551
113. Rovio S., Kareholt I., Helkala E.L., Viitanen M., Winblad B., Tuomilehto J., et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 4 (2005) 705-711
114. Rovio S., Kareholt I., Viitanen M., Winblad B., Tuomilehto J., Soininen H., et al. Work-related physical activity and the risk of dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry 22 (2007) 874-882
115. Ruitenberg A., van Swieten J.C., Witteman J.C.M., Mehta K.M., van Duijn C., Hofman A., et al. Alcohol consumption and risk of dementia: The Rotterdam Study. Lancet 359 (2002) 281-286
116. Schatzkin A., Kipnis V., Carroll R.J., Midthune D., Subar A.F., Bingham S., et al. A comparison of a food frequency questionnaire with a 24-hour recall for use in an epidemiological cohort study: results from the biomarker-based Observing Protein and Energy Nutrition (OPEN) study. Int. J. Epidemiol. 32 (2003) 1054-1062
117. Skoog I., Hesse C., Aevarsson O., Landahl S., Wahlstrom J., Fredman P., et al. A population study of apoE genotype at the age of 85: Relation to dementia, cerebrovascular disease, and mortality. J. Neurol. Neurosurg. Psychiatry 64 (1998) 37-43
118. Slooter A.J., Bronzova J., Witteman J.C., Van Broeckhoven C., Hofman A., and van Duijn C.M. Estrogen use and early onset Alzheimer's disease: a population-based study. J. Neurol. Neurosurg. Psychiatry 67 (1999) 779-781
119. Starkstein S.E., and Jorge R. Dementia after traumatic brain injury. Int. Psychogeriatr. (2005) 17
120. Stewart R., Masaki K., Xue Q.L., Peila R., Petrovitch H., White L.R., et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol. 62 (2005) 55-60
121. Sundstrom A., Nilsson L.-G., Cruts M., Adolfsson R., Van Broeckhoven C., and Nyberg L. Increased risk of dementia following mild head injury for carriers but not for non-carriers of the APOE e5 allele. Int. Psychogeriatr. 19 (2007) 159-165
122. Szekely C.A., Breitner J.C.S., Fitzpatrick A.L., Rea T.D., Psaty B.M., Kuller L.H., et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70 (2008) 17-24
123. Taaffe D.R., Irie F., Masaki K.H., Abbott R.D., Petrovitch H., Ross G.W., et al. Physical activity, physical function, and incident dementia in elderly men: The Honolulu-Asia Aging Study. J. Gerontol. A Biol. Sci. Med. Sci. 63 (2008) 529-535
124. Tanaka N., Asada T., Kinoshita T., Yamashita F., and Uno M. Alcohol consumption and risk of dementia. Lancet 360 (2002) 491
125. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348 (1996) 429-432
126. Tang M.X., Maestre G., Tsai W.Y., Liu X.H., Feng L., Chung W.Y., et al. Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Ann. N. Y. Acad. Sci. 802 (1996) 6-15
127. Tyas S.L., White L.R., Petrovitch H., Webster Ross G., Foley D.J., Heimovitz H.K., et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol. Aging 24 (2003) 589-596
128. Van Duijn C.M., Havekes L.M., Van Broeckhoven C., De Knijff P., and Hofman A. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. Br. Med. J. 310 (1995) 627-631
129. van Oijen M., de Jong F.J., Witteman J.C.M., Hofman A., Koudstaal P.J., and Breteler M.M.B. Atherosclerosis and risk for dementia. Ann. Neurol. 61 (2007) 403-410
130. Vanhanen M., Kivipelto M., Koivisto K., Kuusisto J., Mykkanen L., Helkala E.L., et al. APOE-epsilon4 is associated with weight loss in women with AD: a population-based study. Neurology 56 (2001) 655-659
131. Xu W.L., Qiu C., Winblad B., and Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56 (2007) 211-216
132. Xu W.L., Qiu C.X., Wahlin A., Winblad B., and Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63 (2004) 1181-1186
133. Yip A.G., Green R.C., Huyck M., Cupples L.A., and Farrer L.A. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: The MIRAGE study. BMC Geriatr. (2005) 5
134. Zandi P.P., Carlson M.C., Plassman B.L., and Welsh-Bohmer K.A. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 288 (2002) 2123
135. Zhu L., Fratiglioni L., Guo Z., Winblad B., and Viitanen M. Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project. Neurology 54 (2000) 2103-2107